Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes.

Fonarow GC.

Am J Cardiol. 2004 May 6;93(9A):77B-81B. Review.

PMID:
15144944
2.
3.
4.

Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.

Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J.

Am Heart J. 2004 Jul;148(1):43-51.

PMID:
15215791
5.

Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF.

Fonarow GC.

Rev Cardiovasc Med. 2004;5 Suppl 1:S45-54. Review.

PMID:
15184838
6.

Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Coordinators.

Am Heart J. 2007 Jan;153(1):82.e1-11.

PMID:
17174643
7.

Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?

Fowler MB.

Eur Heart J. 1998 Dec;19 Suppl P:P17-25. Review.

PMID:
9886708
8.
10.

Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review.

Fonarow GC, Gheorghiade M, Abraham WT.

Am J Cardiol. 2004 Nov 1;94(9):1155-60. Review.

PMID:
15518610
11.

Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.

Tarantini L, Cioffi G, Opasich C, Di Lenarda A, Pulignano G, Del Sindaco D, De Feo S, Stefenelli C, Russo P, Catania G.

Ital Heart J. 2004 Jun;5(6):441-9.

PMID:
15320569
12.
13.

Strategies to improve the use of evidence-based heart failure therapies.

Fonarow GC.

Rev Cardiovasc Med. 2005;6 Suppl 2:S32-42. Review.

PMID:
15891703
14.

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.

Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M.

J Am Coll Cardiol. 2001 May;37(6):1692-9.

15.

Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.

Gattis WA, O'Connor CM.

Am J Cardiol. 2004 May 6;93(9A):74B-6B.

PMID:
15144943
16.

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

Circulation. 2002 Oct 22;106(17):2194-9.

17.

How well are chronic heart failure patients being managed?

Fonarow GC.

Rev Cardiovasc Med. 2006;7 Suppl 1:S3-11. Review.

PMID:
16955055
18.

Carvedilol in the failing heart.

Lombardi WL, Gilbert EM.

Clin Cardiol. 2001 Dec;24(12):757-66. Review.

19.

Beta-blocker therapy for heart failure: the standard of care.

Cesario DA, Fonarow GC.

Rev Cardiovasc Med. 2002 Winter;3(1):14-21. Review.

PMID:
12439350
20.

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH.

N Engl J Med. 1996 May 23;334(21):1349-55.

Supplemental Content

Support Center